Cover Image
市場調查報告書

子宮內避孕器 (IUD/IUCD) 的全球 - 2019年為止的預測:荷爾蒙IUCD,銅IUCD

Intrauterine Contraceptive Devices Market (IUD/IUCD), by Type [Hormonal IUCD, Copper IUCD] - Global Forecast to 2019

出版商 MicroMarketMonitor 商品編碼 328129
出版日期 內容資訊 英文 80 Pages
訂單完成後即時交付
價格
Back to Top
子宮內避孕器 (IUD/IUCD) 的全球 - 2019年為止的預測:荷爾蒙IUCD,銅IUCD Intrauterine Contraceptive Devices Market (IUD/IUCD), by Type [Hormonal IUCD, Copper IUCD] - Global Forecast to 2019
出版日期: 2015年04月02日 內容資訊: 英文 80 Pages
簡介

全球子宮內避孕器 (IUCD) 市場在2014年達到33億1,460萬美元規模。預測該市場在2019年前將以年複合成長率6.8%的速度擴大,並達到46億560萬美元。其中銅IUCD市場2014年的市佔率為51.9%,荷爾蒙IUCD則為48.1%。

本報告提供全球子宮內避孕器市場相關資料詳細分析,提供您各類型,各地區的趨勢,並彙整加入此市場的主要企業之詳細競爭趨勢與佔有率,簡介等資料。

第1章 簡介

第2章 調查方法

第3章 摘要整理

第4章 市場概要

  • 簡介
  • 推動市場因素和阻礙因素
  • 市場趨勢

第5章 各類型

  • 簡介
  • 銅IUD
  • 荷爾蒙IUD
  • 女性的避孕市場上類型比較
  • 全球銅補充IUD市場:各地區
  • 全球荷爾蒙IUD市場:各地區

第6章 各產品

  • Mirena
  • Skyla
  • Paragard
  • Essure
  • 開發中產品

第7章 各地區

  • 簡介
  • 亞洲
  • 歐洲
  • 北美
  • 其他

第8章 競爭環境

  • 企業佔有率分析
  • 合併·收購
  • 法律規章認證
  • 夥伴關係
  • 聯合

第9章 各企業市場

  • Bayer Healthcare Ag (Subsidiary of Bayer Ag)
  • Teva Pharmaceutical Industries Ltd.
  • Actavis Plc
  • Medicine360
  • Trimedic Supply Network Ltd.
  • Medisafe Distribution Inc.
  • PACE Pharmaceuticals, Inc.
  • SMB Corporation
  • OCON Medical Ltd.

第10章 附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: HE 1179

The global intrauterine contraceptive devices market is estimated to grow at a CAGR of 6.8% from 2014 to 2019. The growth of the intrauterine contraceptive devices market is driven by factors such as increasing rate of unplanned pregnancies, effective contraception and less side effects of IUCD, implementation of Affordable Care Act (ACA), rising initiatives of private firms directed towards reducing the expenses related to abortion, funds/grants for IUCD products, and technological advancements. However, high cost of treatment, threat of causing pelvic inflammatory infection (PID), threat of causing ectopic pregnancy, high rate of complications during unplanned pregnancy, and need of compulsory assistance of medical professional is hampering the growth of IUCD market. Moreover, rising number of players in this segment, technological advancements are creating growth opportunities for the global intrauterine contraceptive devices market.

In this report, the market has been broadly classified on the basis of types which includes; Hormonal IUCD and Copper IUCD. The copper IUCD market segment is accounted for the largest market share of 51.9%.

Geographically, the market in Asia accounted for the largest share of 35.0% of the Global Intrauterine Contraceptive Devices market in 2014, followed by Europe. The Intrauterine Contraceptive Devices market in the U.S. is primarily driven by Affordable Care Act, technological advancements. However, stringent regulatory and reimbursement policies in U.S., threat to PID infection are hampering the growth of the Intrauterine Contraceptive Devices market in this region.

The global intrauterine contraceptive devices market is a competitive market with a number of market players. Bayer HealthCare AG (A subsidiary of BAYER AG) (Germany), Teva Pharmaceuticals Industries Ltd. (Israel), Actavis Plc. (Ireland), and Medicines360 (Ireland) are some of the major players operating in this market. New product launches and partnerships, agreements, collaborations, and joint ventures are the major strategies adopted by most market players to strengthen their position in this market.

Reasons to Buy the Report:

From an insight perspective, this research report has focused on various levels of analysis-, market share analysis of top players, supply chain analysis, and company profiles, which together comprise and discuss the basic views on the competitive landscape, emerging- and high-growth segments of the global intrauterine contraceptive devices market, high-growth regions and countries and their respective regulatory policies, government initiatives, drivers, restraints, and opportunities.

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help the firms in garnering a greater market share. Firms purchasing the report could use any one or combination of the below mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market share.

The report provides insights on the following pointers:

  • Market Penetration:Comprehensive information on Intrauterine Contraceptive Devices offered by the top players in the Global Intrauterine Contraceptive Devices market
  • Product Development/Innovation:Detailed insights on upcoming technologies, research and development activities, and new product launches in the Global Intrauterine Contraceptive Devices market.
  • Market Development:Comprehensive information about lucrative emerging markets. The report analyzes the markets for various Intrauterine Contraceptive Devices across geographies.
  • Market Diversification:Exhaustive information about new products, untapped geographies, recent developments, and investments in the Global Intrauterine Contraceptive Devices market.
  • Competitive Assessment:In-depth assessment of market shares, strategies, products, and manufacturing capabilities of leading players in the Global Intrauterine Contraceptive Devices market.

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET SEGMENTATION & COVERAGE

2. RESEARCH METHODOLOGY

  • 2.1. INTEGRATED ECOSYSTEM OF INTRAUTERINE CONTRACEPTIVE DEVICES MARKET
  • 2.2. ARRIVING AT THE GLOBAL INTRAUTERINE CONTRACEPTIVE DEVICES MARKET SIZE
    • 2.2.1. TOP-DOWN APPROACH
    • 2.2.2. BOTTOM-UP APPROACH
    • 2.2.3. MACRO INDICATOR-BASED APPROACH
  • 2.3. ASSUMPTIONS

3. EXECUTIVE SUMMARY

4. MARKET OVERVIEW

  • 4.1. INTRODUCTION
  • 4.2. MARKET DRIVERS AND INHIBITORS
  • 4.3. KEY MARKET DYNAMICS

5. GLOBAL INTRAUTERINE CONTRACEPTIVE DEVICES MARKET, BY TYPE

  • 5.1. INTRODUCTION
  • 5.2. COPPER IUD
  • 5.3. HORMONAL IUD
  • 5.4. GLOBAL INTRAUTERINE CONTRACEPTIVE DEVICES MARKET, TYPE COMPARISON WITH FEMALE CONTRACEPTIVES MARKET
  • 5.5. GLOBAL COPPER IUD MARKET, BY GEOGRAPHY
  • 5.6. GLOBAL HORMONAL IUD MARKET, BY GEOGRAPHY

6. GLOBAL INTRAUTERINE CONTRACEPTIVE DEVICES MARKET, BY PRODUCT

  • 6.1. MIRENA
    • 6.1.1. PRODUCT POSITIONING AND PROMOTIONS OF MIRENA
  • 6.2. SKYLA
    • 6.2.1. PRODUCT POSITIONING AND PROMOTIONS OF SKYLA
  • 6.3. PARAGARD
    • 6.3.1. PRODUCT POSITIONING AND PROMOTIONS OF PARAGARD
  • 6.4. ESSURE
    • 6.4.1. PRODUCT POSITIONING AND PROMOTIONS OF ESSURE
  • 6.5. PIPELINE PRODUCTS
    • 6.5.1. LEVOSERT

7. GLOBAL INTRAUTERINE CONTRACEPTIVE DEVICES MARKET, BY GEOGRAPHY

  • 7.1. INTRODUCTION
  • 7.2. ASIA : INTRAUTERINE CONTRACEPTIVE DEVICES MARKET
  • 7.3. EUROPE : INTRAUTERINE CONTRACEPTIVE DEVICES MARKET, BY GEOGRAPHY
  • 7.4. NORTH AMERICA : INTRAUTERINE CONTRACEPTIVE DEVICES MARKET, BY GEOGRAPHY
  • 7.5. ROW INTRAUTERINE CONTRACEPTIVE DEVICES MARKET, BY GEOGRAPHY

8. GLOBAL INTRAUTERINE CONTRACEPTIVE DEVICES MARKET: COMPETITIVE LANDSCAPE

  • 8.1. GLOBAL INTRAUTERINE CONTRACEPTIVE DEVICES MARKET: COMPANY SHARE ANALYSIS
  • 8.2. MERGERS & ACQUISITIONS
  • 8.3. REGULATORY APPROVALS
  • 8.4. PARTNERSHIP
  • 8.5. COLLABORATION

9. GLOBAL INTRAUTERINE CONTRACEPTIVE DEVICES MARKET, BY COMPANY (Overview, Financials, Products & Services, Strategy, and Developments)*

  • 9.1. BAYER HEALTHCARE AG (SUBSIDIARY OF BAYER AG)
  • 9.2. TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • 9.3. ACTAVIS PLC
  • 9.4. MEDICINE360
  • 9.5. TRIMEDIC SUPPLY NETWORK LTD.
  • 9.6. MEDISAFE DISTRIBUTION INC.
  • 9.7. PACE PHARMACEUTICALS, INC.
  • 9.8. SMB CORPORATION
  • 9.9. OCON MEDICAL LTD.

*Details on overview, financials, product & services, strategy, and developments might not be captured in case of unlisted company

10. APPENDIX

  • 10.1. RELATED REPORTS
  • 10.2. INTRODUCING RT: REAL TIME MARKET INTELLIGENCE
    • 10.2.1. RT SNAPSHOTS

LIST OF TABLES

  • TABLE 1: GLOBAL INTRAUTERINE CONTRACEPTIVE DEVICES MARKET: MACRO INDICATORS, BY REGION, 2008 (ABORTION PER 1000 WOMEN AGES 15-44)
  • TABLE 2: GLOBAL INTRAUTERINE CONTRACEPTIVE DEVICES MARKET: DRIVERS AND INHIBITORS
  • TABLE 3: GLOBAL INTRAUTERINE CONTRACEPTIVE DEVICES MARKET: COMPARISON WITH GLOBAL FEMALE CONTRACEPTIVES MARKET, 2013 - 2019 (USD MN)
  • TABLE 4: GLOBAL INTRAUTERINE CONTRACEPTIVE DEVICES MARKET, BY GEOGRAPHY, 2013 - 2019 (USD MN)
  • TABLE 5: GLOBAL INTRAUTERINE CONTRACEPTIVE DEVICES MARKET, BY TYPE, 2013 - 2019 (USD MN)
  • TABLE 6: GLOBAL INTRAUTERINE CONTRACEPTIVE DEVICES MARKET: TYPE COMPARISON WITH FEMALE CONTRACEPTIVES MARKET, 2013-2019 (USD MN)
  • TABLE 7: GLOBAL COPPER IUD MARKET, BY GEOGRAPHY, 2013 - 2019 (USD MN)
  • TABLE 8: GLOBAL COPPER IUD MARKET, BY GEOGRAPHY, 2013 - 2019 (USD MN)
  • TABLE 9: GLOBAL INTRAUTERINE CONTRACEPTIVE DEVICES MARKET, BY GEOGRAPHY , 2013 - 2019 (USD MN)
  • TABLE 10: GLOBAL INTRAUTERINE CONTRACEPTIVE DEVICES MARKET, BY TYPE, 2013 -2019 (USD MN)
  • TABLE 11: ASIA :INTRAUTERINE CONTRACEPTIVE DEVICES MARKET, BY GEOGRAPHY, 2013-2019 (USD MN)
  • TABLE 12: ASIA : INTRAUTERINE CONTRACEPTIVE DEVICES MARKET, BY TYPE, 2013-2019 (USD MN)
  • TABLE 13: EUROPE : INTRAUTERINE CONTRACEPTIVE DEVICES MARKET, BY GEOGRAPHY, 2013-2019 (USD MN)
  • TABLE 14: EUROPE : INTRAUTERINE CONTRACEPTIVE DEVICES MARKET, BY TYPE
  • TABLE 15: NORTH AMERICA : INTRAUTERINE CONTRACEPTIVE DEVICES MARKET, BY GEOGRAPHY
  • TABLE 16: NORTH AMERICA : INTRAUTERINE CONTRACEPTIVE DEVICES MARKET, BY TYPE
  • TABLE 17: ROW INTRAUTERINE CONTRACEPTIVE DEVICES MARKET, BY GEOGRAPHY
  • TABLE 18: ROW INTRAUTERINE CONTRACEPTIVE DEVICES MARKET, BY TYPE
  • TABLE 19: GLOBAL INTRAUTERINE CONTRACEPTIVE DEVICES MARKET: COMPANY SHARE ANALYSIS, 2013 (%)
  • TABLE 20: GLOBAL INTRAUTERINE CONTRACEPTIVE DEVICES MARKET: MERGERS & ACQUISITIONS
  • TABLE 21: GLOBAL INTRAUTERINE CONTRACEPTIVE DEVICES MARKET: REGULATORY APPROVALS
  • TABLE 22: GLOBAL INTRAUTERINE CONTRACEPTIVE DEVICES MARKET: PARTNERSHIP
  • TABLE 23: GLOBAL INTRAUTERINE CONTRACEPTIVE DEVICES MARKET: COLLABORATION
  • TABLE 24: BAYER HEALTHCARE AG.: KEY FINANCIALS, 2008 - 2013 (USD MN)
  • TABLE 25: TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY FINANCIALS, 2008 - 2013 (USD MN)
  • TABLE 26: ACTAVIS PLC: KEY FINANCIALS, 2008 - 2013 (USD MN)

LIST OF FIGURES

  • FIGURE 1: EVOLUTION OF INTRAUTERINE CONTRACEPTIVE DEVICES (IUD/IUCD)
  • FIGURE 2: GLOBAL INTRAUTERINE CONTRACEPTIVE DEVICES MARKET: SEGMENTATION & COVERAGE
  • FIGURE 3: INTRAUTERINE CONTRACEPTIVE DEVICES MARKET: INTEGRATED ECOSYSTEM
  • FIGURE 4: TOP-DOWN APPROACH
  • FIGURE 5: BOTTOM-UP APPROACH
  • FIGURE 6: MACRO INDICATOR-BASED APPROACH
  • FIGURE 7: GLOBAL INTRAUTERINE CONTRACEPTIVE DEVICES MARKET SNAPSHOT
  • FIGURE 8: GLOBAL INTRAUTERINE CONTRACEPTIVE DEVICES MARKET: COMPARISON WITH GLOBAL FEMALE CONTRACEPTIVES MARKET
  • FIGURE 9: GLOBAL INTRAUTERINE CONTRACEPTIVE DEVICES, BY REGION, 2014 & 2019 (USD MN)
  • FIGURE 10: GLOBAL INTRAUTERINE CONTRACEPTIVE DEVICES MARKET, BY TYPE, 2014 & 2019 (USD MN)
  • FIGURE 11: ADVANTAGES & DISADVANTAGES OF COPPER IUD
  • FIGURE 12: ADVANTAGES & DISADVANTAGES OF HORMONAL IUD
  • FIGURE 13: GLOBAL INTRAUTERINE CONTRACEPTIVE DEVICES MARKET, BY TYPE, 2012 - 2018 (USD MN)
  • FIGURE 14: GLOBAL INTRAUTERINE CONTRACEPTIVE DEVICES MARKET: TYPE COMPARISON WITH FEMALE CONTRACEPTIVES MARKET, 2013-2019 (USD MN)
  • FIGURE 15: GLOBAL COPPER IUD MARKET, BY GEOGRAPHY , 2013 - 2019 (USD MN)
  • FIGURE 16: GLOBAL HORMONAL IUD MARKET, BY GEOGRAPHY, 2013 - 2019 (USD MN)
  • FIGURE 17: ADVERSE EFFECTS CAUSED BY MIRENA, U.S., 1997-2012
  • FIGURE 18: ASIA : INTRAUTERINE CONTRACEPTIVE DEVICES MARKET, BY GEOGRAPHY
  • FIGURE 19: ASIA : INTRAUTERINE CONTRACEPTIVE DEVICES MARKET, BY TYPE
  • FIGURE 20: ASIA: INTRAUTERINE CONTRACEPTIVE DEVICES MARKET, BY TYPE
  • FIGURE 21: ASIA : INTRAUTERINE CONTRACEPTIVE DEVICES MARKET: BY TYPECOMPARISION WITH FEMALE CONTRACEPTIVE DEVICES MARKET (2013-2019)
  • FIGURE 22: ASIA : COPPER INTRAUTERINE CONTRACEPTIVE DEVICES MARKET, (2013-2019)
  • FIGURE 23: ASIA: HORMONAL INTRAUTERINE CONTRACEPTIVE DEVICES MARKET, (2013-2019)
  • FIGURE 24: EUROPE : INTRAUTERINE CONTRACEPTIVE DEVICES MARKET, BY GEOGRAPHY
  • FIGURE 25: EUROPE : INTRAUTERINE CONTRACEPTIVE DEVICES MARKET, BY TYPE
  • FIGURE 26: EUROPE : INTRAUTERINE CONTRACEPTIVE DEVICES MARKET, BY TYPES
  • FIGURE 27: EUROPE : INTRAUTERINE CONTRACEPTIVE DEVICES MARKET: BY TYPE COMPARISON WITH FEMALE CONTRACEPTIVE DEVICES MARKET (2013-2019)
  • FIGURE 28: EUROPE : COPPER INTRAUTERINE CONTRACEPTIVE DEVICES MARKET, (2013-2019)
  • FIGURE 29: EUROPE : HORMONAL INTRAUTERINE CONTRACEPTIVE DEVICES MARKET, (2013-2019)
  • FIGURE 30: NORTH AMERICA : INTRAUTERINE CONTRACEPTIVE DEVICES MARKET, BY GEOGRAPHY
  • FIGURE 31: NORTH AMERICA : INTRAUTERINE CONTRACEPTIVE DEVICES MARKET, BY TYPES
  • FIGURE 32: NORTH AMERICA : INTRAUTERINE CONTRACEPTIVE DEVICES MARKET, BY TYPE
  • FIGURE 33: NORTH AMERICA :INTRAUTERINE CONTRACEPTIVE DEVICES MARKET: BY TYPES COMPARISON WITH FEMALE CONTRACEPTIVE DEVICES MARKET (2013-2019)
  • FIGURE 34: NORTH AMERICA : HORMONAL INTRAUTERINE CONTRACEPTIVE DEVICES MARKET, (2013-2019)
  • FIGURE 35: NORTH AMERICA : COPPER INTRAUTERINE CONTRACEPTIVE DEVICES MARKET, (2013-2019)
  • FIGURE 36: ROW INTRAUTERINE CONTRACEPTIVE DEVICES MARKET, BY GEOGRAPHY
  • FIGURE 37: ROW INTRAUTERINE CONTRACEPTIVE DEVICES MARKET, BY TYPE
  • FIGURE 38: ROW INTRAUTERINE CONTRACEPTIVE DEVICES MARKET, BY TYPES
  • FIGURE 39: ROW INTRAUTERINE CONTRACEPTIVE DEVICES MARKET: BY TYPES COMPARISON WITH FEMALE CONTRACEPTIVE DEVICES MARKET (2013-2019)
  • FIGURE 40: ROW HORMONAL INTRAUTERINE CONTRACEPTIVE DEVICES MARKET, 2013-2019
  • FIGURE 41: ROW COPPER INTRAUTERINE CONTRACEPTIVE DEVICES MARKET, (2013-2019)
  • FIGURE 42: GLOBAL INTRAUTERINE CONTRACEPTIVE DEVICES MARKET: COMPANY SHARE ANALYSIS, 2013 (%)
  • FIGURE 43: BAYER HEALTHCARE AG: REVENUE MIX (2013) (%)
  • FIGURE 44: CONTRIBUTION OF PHARMACEUTICALS SEGMENT TOWARDS COMPANY REVENUES, 2008-2013 (USD MN)
  • FIGURE 45: TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE MIX (2013) (%)
  • FIGURE 46: CONTRIBUTION OF SPECIALITY MEDICINE SEGMENT TOWARDS COMPANY REVENUES, 2008-2013 (USD MN)
  • FIGURE 47: ACTAVIS PLC: REVENUE MIX (2013) (%)
Back to Top